Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

WT1 (WT1 Transcription Factor)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

WT1 mutation	Acute Myelogenous Leukemia	WT1 mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
FLT3‐ITD + WT1 mutation	Acute Myelogenous Leukemia	FLT3‐ITD + WT1 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B
WT1 mutation	Acute Myelogenous Leukemia	WT1 mutation	Acute Myelogenous Leukemia	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3
WT1 expression	Malignant Pleural Mesothelioma	WT1 expression	Malignant Pleural Mesothelioma	nivolumab + galinpepimut-S Sensitive: C3 – Early Trials nivolumab + galinpepimut-S Sensitive : C3	nivolumab + galinpepimut-S Sensitive: C3 – Early Trials nivolumab + galinpepimut-S Sensitive : C3
WT1 expression	Ovarian Cancer	WT1 expression	Ovarian Cancer	pembrolizumab + galinpepimut-S Sensitive: C3 – Early Trials pembrolizumab + galinpepimut-S Sensitive : C3	pembrolizumab + galinpepimut-S Sensitive: C3 – Early Trials pembrolizumab + galinpepimut-S Sensitive : C3
WT1 underexpression	Acute Myelogenous Leukemia	WT1 underexpression	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3
IDH1 mutation + WT1 overexpression	Glioblastoma	IDH1 mutation + WT1 overexpression	Glioblastoma	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
WT1 overexpression	Myelodysplastic Syndrome	WT1 overexpression	Myelodysplastic Syndrome	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3
WT1 overexpression	Myelodysplastic Syndrome	WT1 overexpression	Myelodysplastic Syndrome	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3
WT1 overexpression	Acute Myelogenous Leukemia	WT1 overexpression	Acute Myelogenous Leukemia	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3
FLT3-ITD mutation + WT1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + WT1 mutation	Acute Myelogenous Leukemia	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3
FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression	Acute Promyelocytic Leukemia	FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression	Acute Promyelocytic Leukemia	cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive: C4 – Case Studies cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive : C4	cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive: C4 – Case Studies cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive : C4